Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Eyetech To Become Full OSI Subsidiary Under $935 Mil. Deal

This article was originally published in The Pink Sheet Daily

  • News
  • Andrew Shelton

Executive Summary

OSI's acquisition of Macugen developer Eyetech will pit the company against its Tarceva partner Genentech in the macular degeneration market.

You may also be interested in...



OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results

OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.

OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results

OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.

Genentech/OSI's Tarceva Given Sept. 13 Cmte. Review For Pancreatic Cancer

Supplemental NDA is based on a single Phase III trial of Tarceva plus Lilly's Gemzar vs. Gemzar and placebo.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS062759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By